Figure 3.
Gene Set Enrichment Analysis (GSEA) suggested that the combination of Bevacizumab and Temozolomide activated genes related to immunocyte migration (myeloid leukocyte migration, leukocyte chemotaxis, and lymphocyte migration/ chemotaxis), but suppressed genes related to the cell cycle (DNA replication, mitotic recombination, chromosome condensation, and DNA strand elongation) in IDH1-mutant U87 cells.